Daprodustat

(Jesduvroq®)

Jesduvroq®

Drug updated on 11/17/2023

Dosage FormTablet (oral: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg)
Drug ClassHypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months.

Product Monograph / Prescribing Information

Document TitleYearSource
Jesduvroq (daprodustat) Prescribing Information. 2023GlaxoSmithKline, Durham, NC

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis. 2023Frontiers in Pharmacology
Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review. 2023Cureus
A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. 2023Aging
Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials.2022European Journal of Clinical Pharmacology
Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis. 2022Frontiers in Pharmacology
Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease. 2022Cochrane Database of Systematic Reviews
Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis. 2022Clinical and Experimental Nephrology
Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. 2022Therapeutic Apheresis and Dialysis
Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients. 2021Journal of Clinical Pharmacy and Therapeutics
Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. 2021Frontiers in Pharmacology
Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. 2020Renal Failure
Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis. 2018International Urology and Nephrology